Complete solutions for Targeted Protein Degradation and PROTACs

Syngene brings to you widely recognized expertise in Targeted Degradation (X-TACs), with 200+ scientists working on harnessing the ubiquitin-proteasome pathway

To get a quote or book a meeting with our experts, fill in the form below.

Syngene is the expert partner you have been looking for, who can support you from the very start of your protein degradation journey all the way through to the clinic. We have extensive experience working in this space, particularly in the field of heterobifunctional degraders (Linkers – alcohols, halides, acids, amines; Ligands for E3 Ligases -CRBN, VHL, IAP, MDM2). We have supported our clients from early discovery to development to candidate selection, for multiple targets. We are also expanding our capabilities to support programs based on molecular glues, RIBOTACs, LYTACs, and more. Our experience allows us to create a roadmap for your X-TACs research program, supported at each stage by strong supply chain, logistics, program management, and data security teams.

Proteolysis Targeting Chimeras (PROTACs)

Molecular Glues

Ribonuclease Targeting Chimeras (RIBOTACs)

Our experience and impact

We have run several Protein Degradation programs, and contributed to the discovery of two PROTAC clinical candidates

Client
Mode of degradation
Number of projects
US based biotech
Molecular glues and PROTACs
7 projects (enabled advancement of 2 projects to candidate selection)
UK based large pharma
PROTACs
Multiple projects
US based biotech
RIBOTACs
Multiple projects
US based start-up
Molecular glues
Multiple projects
US based biotech
PROTACs
Multiple projects
UK based biotech
PROTACs
Multiple projects
Korea based biotech
PROTACs
One project
US based VC
PROTACs
One project

Our capabilities address key challenges of heterobifunctional degrader discovery

Chemistry

Biology

DMPK/Druggability

Our services span across Hit-ID, CADD-based X-TACs design, Synthesis, Optimization, Purification, Screening, and ADME-PK

Resources

Science in 3 Minutes: Targeted Protein Degradation

Watch this 3-minute video for insights into the novel modality of Targeted Protein Degradation , and the impact that Syngene is able to deliver to clients working on PROTACs.

Play Video
Play Video

RNA-targeted small molecule discovery approaches

Understand more about RNA-targeted small molecule discovery, including current drug discovery approaches and emerging areas of interest, such as RIBOTACs, Epitranscriptomics, and target validation methodologies.

Take a 360° virtual tour of our labs

You can now take a 360-degree virtual tour of our facilities that enable our Targeted Protein Degradation services across Chemistry, Assay Biology, DPMK and more. Start your tour now!

Syngene International Limited. All rights reserved © 2021.  |   Privacy policy

To download, Please share your details

To download, Please share your details